List of Cabometyx drug patents

Cabometyx is owned by Exelixis Inc.

Cabometyx contains Cabozantinib S-Malate.

Cabometyx has a total of 11 drug patents out of which 0 drug patents have expired.

Cabometyx was authorised for market use on 25 April, 2016.

Cabometyx is available in tablet;oral dosage forms.

Cabometyx can be used as treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; treatment of renal cell carcinoma; treatment of advanced renal cell carcinoma; treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy, treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy, treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib, treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy, treatment of renal cell carcinoma; treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; treatment of advanced renal cell carcinoma, treatment of advanced renal cell carcinoma.

The generics of Cabometyx are possible to be released after 17 April, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473 EXELIXIS INC c-Met modulators and methods of use
Aug, 2026

(3 years from now)

US11091439 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(6 years from now)

US8877776 EXELIXIS INC (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(1 year, 7 months from now)

US11091440 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions
Jul, 2031

(8 years from now)

US10034873 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2031

(8 years from now)

US11298349 EXELIXIS INC Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(9 years from now)

US9724342 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2033

(10 years from now)

US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
Apr, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma; Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy; Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic